As part of the ISCT 2024 Translational Pathway Sessions, as well as the ISCT main program, Aspen's Chief Scientific Officer Xiaokui Zhang, Ph.D., and Chief Technology Officer Kim Raineri will discuss developments in autologous research and development, including for ANPD001, Aspen's autologous iPSC-derived neuron replacement therapy currently under investigation for Parkinson's disease in a Phase 1/2a clinical trial, as well as advancements in manufacturing of autologous iPSCs. Daniel Fremgen, Director of Analytical Development, will present regarding Aspen analytical development strategy including machine learning genomic models and characterization of autologous iPSCs and dopaminergic neuron precursor cells.
Thursday, May 30
Event:
ISCT 2024 Translational Pathway Sessions –
Translation to Clinic Concurrent Session
Title:
Autologous iPSC-Derived Neuron Replacement for Parkinson's Disease
Chair and
Presenter:
Xiaokui Zhang, Ph.D.
Chief Scientific Officer, Aspen Neuroscience
Time:
5:00 - 6:00pm PT
Location:
Room 217-219
Event:
Scientific Poster Sessions –
Poster Networking Session #2
Title:
Analytical Development Strategy for Dopaminergic Neuron Precursor Cell
Replacement Therapy for Parkinson's Disease
Presenter:
Daniel Fremgen
Director, Analytical Development, Aspen Neuroscience
Time:
6:00 - 7:30pm PT
Location:
Exhibit & Poster Hall
Saturday, June 1
iPSCs Signature Series: From Bench to Bedside
Event:
Manufacturing Considerations for Autologous and Allogeneic iPSC-derived
Therapies & Opportunities for Cross-industry Alignment
Title:
Manufacturing of Autologous iPSCs
Presenter:
Kim Raineri
Chief Technology Officer, Aspen Neuroscience
Time:
8:15 - 9:15am PT
Event:
Characterization of iPSC-derived Cell Therapies – Going in Depth
Chair
Xiaokui Zhang, PhD
Title:
Characterization of Autologous iPSCs and Dopaminergic Neuron Precursor
Cells for Parkinson's Disease
Presenter:
Daniel Fremgen
Director, Analytical Development, Aspen Neuroscience
Time:
10:30 - 11:30am PT
